Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
39results about How to "Broad-spectrum antiviral activity" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Applications of dihydromyricetin in preparation of anti-influenza virus drugs
InactiveCN108354923ALow toxicitySafe and efficient developmentOrganic active ingredientsAntiviralsPhenylalanineHistidine
The invention discloses applications of dihydromyricetin in preparation of anti-influenza virus drugs, wherein influenza virus is influenza A virus, preferably H1N1, H3N2, H5N1, H7N1, H7N2, H7N3, H7N7, H7N9, H9N2 or H10N8. According to the present invention, the anti-influenza A virus action mechanism of the dihydromyricetin is that the activity of the ribonucleoprotein complex vRNP is inhibited by binding the dihydromyricetin to the PB2cap protein so as to prepare the drugs for prevention and treatment of influenza, wherein the binding loci of the dihydromyricetin and the PB2cap protein are site-432 histidine (His432), site-357 histidine (His357), site-404 phenylalanine (Phe404), site-323 Phenylalanine (Phe323), site-361 glutamic acid (Glu361), site-376 lysine (Lys376), site-363 phenylalanine (Phe363), and site-429 asparagine (Asn429).
Owner:SOUTHERN MEDICAL UNIVERSITY
Fatty acid complex
ActiveCN108605933ABroad-spectrum bactericidal activityBroad-spectrum antiviral activityBiocideFruit and vegetables preservationEscherichia coliOctanoic Acids
The invention discloses a fatty acid complex. The fatty acid complex comprises the following components in parts by weight: 2.2-3 parts of mixed fatty acid, 16-40 parts of a surfactant and 40-60 partsof auxiliary acid, wherein the mixed fatty acid is a mixture of octanoic acid, nonoic acid and capric acid; the auxiliary acid is lauric acid or a mixture of the lauric acid and citric acid. The fatty acid complex has broad-spectrum bactericidal and antiviral activity, can kill polioviruses, foot-and-mouth disease viruses, porcine reproductive and respiratory syndrome viruses and avian influenzaviruses, has the staphylococcus aureus and escherichia coli killing rate as high as 99.99999%; the fatty acid complex has excellent storage stability under a diluted condition, is applied to a food disinfectant, has an excellent food preserving function, is free of cleaning during disinfection, free of metal corrosion, practically non-toxic and non-irritant to skin, and is unlikely to volatilize;the fatty acid complex has acidic pH and a light coconut scent, disinfecting cleaning sewage does not pollute the environment, and the fatty acid complex can be reused in some disinfecting scenes.
Owner:上海康归生物科技有限公司
Application of dendrobine in preparation of anti-influenza virus medicines
ActiveCN106138040ABroad-spectrum antiviral activityReduce immune cross-protection effectOrganic active ingredientsAntiviralsDendrobineRibonucleoprotein complex
The invention discloses application of dendrobine in preparation of anti-influenza virus medicines. The influenza virus is influenza a virus, preferably H1N1, H3N2, H5N1, H7N1, H7N2, H7N3, H7N7, H7N9, H9N2 or H10N8. The dendrobine can be used for preparing medicines capable of inhibiting replication of influenza a virus in host cells, and is capable of inhibiting denucleation of a virus ribonucleoprotein complex vRNP or activity of the ribonucleoprotein complex vRNP, wherein loci at which the dendrobine is combined with influenza virus NP proteins are Arg267 at locus 267, Val270 at locus 270, Phe338 at locus 338 and Glu339 at locus 339.
Owner:SOUTHERN MEDICAL UNIVERSITY
Application of myricetin in preparation of anti-influenza-virus drugs
InactiveCN107898778ALow toxicitySafe and efficient developmentOrganic active ingredientsAntiviralsPhenylalanineHistidine
The invention discloses application of myricetin in the preparation of anti-influenza-virus drugs. Influenza A virus is referred to herein, preferably, H1N1, H3N2, H5N1, H7N1, H7N2, H7N3, H7N7, H7N9,H9N2 or H10N8. The acting mechanism of myricetin to resist influenza A virus is to inhibit activity of ribonucleoprotein complex vRNP by combination with PB2cap protein; myricetin is applicable to thepreparation of drugs to prevent and treat influenza viruses, wherein sites of myricetin combined with influenza virus PB2cap protein are histidine at 357 (His357), phenylalanine at 404 (Phe404), phenylalanine at 323 (Phe323), glutamic acid at 361 (Glu361), lysine at 376 (Lys376), phenylalanine at 363 (Phe363) and asparagine at 429 (Asn429).
Owner:SOUTHERN MEDICAL UNIVERSITY
Application of chlorpheniramine maleate in preparation of medicaments for treating or preventing influenza virus
InactiveCN103239446AInhibition of adsorptionInhibit entryOrganic active ingredientsAntiviralsVirus strainInfluenza a
The invention discloses application of chlorpheniramine maleate in preparation of medicaments for treating or preventing influenza virus. The application comprises the following steps of: first, performing an antivirus experiment by selecting the chlorpheniramine maleate with completely non-toxic concentration, wherein the result shows that the low molecular weight compound has remarkable antiviral activity and has dose-dependent correlation; then, analyzing the anti-influenza virus action cycle of chlorpheniramine maleate, wherein the result shows that chlorpheniramine maleate mainly inhibits the early virus infection events of virus adsorption, entry and the like; and finally, detecting the antiviral activity of chlorpheniramine maleate on different types or subtypes of influenza virus, wherein the result shows that chlorpheniramine maleate can inhibit the replication of all detection virus strains and has a dose-dependent effect, and shows that the anti-influenza virus activity of chlorpheniramine maleate has certain broad spectrum. Therefore, chlorpheniramine maleate disclosed by the invention can be developed as a new anti-influenza virus medicament, and provides a new way and a new means for treating the influenza virus.
Owner:WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
Edible antiviral sterilization washing liquid
InactiveCN1631236AEasy to killEnhanced inhibitory effectOrganic detergent compounding agentsFood preparationChinese cinnamonGleditsia triacanthos
The invention provides an edible antiviral sterilization washing liquid, which is prepared from water, edible vinegar concentrate, edible vinegar, toasted garlic, onion, clove, Cinnamomum cassia, mace nutmeg, wild marjoram, pepper, grape, thyme, Chinese honey locust and sodium benzoate as raw material through conventional process. The liquid has multiple functions including enhancing human body immunity.
Owner:杨毅男
Application of enilconazole in preparing drug for treating or preventing influenza virus infections
InactiveCN103705506AImprove securityBroad-spectrum antiviral activityOrganic active ingredientsAntiviralsPharmaceutical SubstancesVirus strain
The invention discloses an application of enilconazole in preparing a drug for treating or preventing influenza virus infections. Firstly, toxicity of enilconazole to MDCK cells is detected. The result shows that the maximum non-toxic concentration of enilconazole is 100.0 [mu]M. Secondly, antiviral activity of enilconazole is measured within a completely non-toxic concentration range. The result shows that the small molecular compound has significant antiviral activity and the antiviral activity presents a dosage-dependent effect. Finally, the antiviral activities of enilconazole to influenza viruses in different types and subtypes are detected. The results show that enilconazole can suppress replication of all the detected influenza virus strains in a dose-dependent manner, so that the anti-influenza virus activity of enilconazole has a broad spectrum. Therefore, enilconazole disclosed by the invention is a novel broad-spectrum anti-influenza virus drug and can be used for preparing the drug for treating or preventing the influenza virus infections.
Owner:武汉威立得生物医药有限公司
Application of carbinoxamine maleate in preparation of anti-influenza virus medicine
ActiveCN110870864AAvoid infectionBroad-spectrum antiviral activityOrganic active ingredientsAntiviralsEndocytosis InhibitionDose dependence
The invention belongs to the technical field of medicine, and relates to an application of carbinoxamine maleate in preparation of an anti-influenza virus medicine. Experiments show that the carbinoxamine maleate has significant anti-influenza activity against different types and subtypes of influenza viruses in a completely non-toxic concentration environment, and inhibits the replication of alltested virus strains in a dose-dependent manner, so that the results indicate that the anti-influenza virus activity of the carbinoxamine maleate has a certain broad spectrum; influenza viruses described in the invention include influenza A and B viruses, including H1N1, H3N2, H7N9, H5N1, H7N1, H7N2, H7N3, H7N7, H9N2 or B type; the action mechanism study provided by the invention shows that the carbinoxamine maleate mainly inhibits the viruses from entering host cells by interfering with the endocytosis of the influenza viruses; and the carbinoxamine maleate can be used to prepare the medicinefor preventing and treating influenza, and provides a novel way and means for the prevention and treatment of the influenza.
Owner:FUDAN UNIV
Racemic and chiral 3-(2, 3-butadienyl)oxoindolone compound, and preparation method and application thereof
ActiveCN113548999AInhibitory activity hasBroad-spectrum antiviral activityOrganic active ingredientsOrganic chemistry methodsPtru catalystPalladium catalyst
The invention discloses a racemic and chiral 3-(2, 3-butadienyl)oxoindolone compound, a method for preparing the compound by adopting a palladium-catalyzed coupling reaction, and application of the compound. According to the method, 2, 3-butadienyl carbonate and oxoindolone react in an organic solvent in the presence of a palladium catalyst to directly construct the racemic 3-(2, 3-butadienyl)oxoindolone compound in one step. If the palladium catalyst and the chiral phosphine ligand are used in a system and react in then organic solvent, the chiral 3-(2, 3-butadienyl)oxoindolone compound can be directly constructed in one step, and the compound can be easily converted into other complex molecules. The method is convenient to operate, raw materials and reagents are easy to obtain, the substrate universality is wide, the functional group compatibility is good, and the reaction has good conversion rate and high enantioselectivity and chemical selectivity. Besides, the 3-(2, 3-butadienyl)oxoindolone compound and related derivatives thereof provided by the invention can be combined with SRAS-CoV-2 main protein 3CL hydrolase, and have a good application prospect in the aspect of treating human virus infection.
Owner:FUDAN UNIV
Application of diphenhydramine hydrochloride in preparation of medicines for treating or preventing influenza viruses
InactiveCN103251576ABroad-spectrum antiviral activityInhibition of replicationOrganic active ingredientsAntiviralsDrugToxicity
The invention discloses an application of diphenhydramine hydrochloride in preparation of medicines for treating or preventing influenza viruses. Firstly, diphenhydramine hydrochloride with completely nontoxic concentration is selected for an antiviral test, and the result shows that the small molecular compound has remarkable antiviral activity and is in dose-dependent association; then, the action period of diphenhydramine hydrochloride which resists influenza viruses is analyzed, and the result shows that diphenhydramine hydrochloride mainly inhibits events in early stage of virus infection such as virus absorption and entrance; and finally, the antiviral activity of diphenhydramine hydrochloride to different types and sub-types of influenza viruses is detected, and the result shows that diphenhydramine hydrochloride can inhibit replication of all detection viral strains and has the dose-dependent effect, thereby representing that diphenhydramine hydrochloride is of certain broad spectrum to anti-influenza virus activity. The diphenhydramine hydrochloride disclosed by the invention can be developed as a novel anti-influenza virus medicine and provides a novel path and means for treating influenza.
Owner:WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
Application of GW3965 in preparation of drugs treating or preventing hepatitis C
InactiveCN103054844BAvoid infectionHigh selectivityPeptide/protein ingredientsDigestive systemHcv hepatitis c virusPhenylacetic acid
Owner:WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
Application of benzydamine hydrochloride in preparation of medicine for treating or preventing influenza virus infection
ActiveCN103893171BImprove securityInhibition of replicationOrganic active ingredientsAntiviralsBenzydamine HydrochlorideViral infection
The invention relates to the technical field of medicines and in particular discloses an application of benzydamine hydrochloride in preparing a medicament for preventing or treating influenza virus infections. Firstly, the toxicity of benzydamine hydrochloride for an MDCK cell is detected, and a result shows that the maximum nontoxicity concentration of benzydamine hydrochloride is 50.0 mu M; secondly, the antiviral activity of benzydamine hydrochloride is measured in the safe and nontoxic concentration range, and a result shows that the small molecule compound has remarkable antiviral activity and the antiviral effect has a dose-dependent effect; finally, the antiviral activity of benzydamine hydrochloride for different types and subtypes of influenza viruses is detected, and a result shows that benzydamine hydrochloride can inhibit replication of all detected influenza virus strains in a dose-dependent manner and the anti-influenza virus activity of benzydamine hydrochloride has broad spectrum. Therefore, the invention discloses benzydamine hydrochloride as a novel broad-spectrum anti-influenza virus medicament for the first time. Benzydamine hydrochloride can be used for preparing the medicament for preventing or treating influenza virus infections.
Owner:佛山熠然生物科技有限公司
Antiviral bactericidal purifying cleaning liquid
InactiveCN1687350AEasy to killEnhanced inhibitory effectNon-surface-active detergent compositionsHot peppersOriganum
The present invention relates to an antiviral bacteria-killing cleaning detergent with several health-care functions. Said cleaning detergent is made up by using the raw materials of water, edible acetin, edible vinegar, garlic, onion, clove, cinnamon bark, nutmeg, origanum, hot pepper, grape, thymus mongolicus, gleditsia fruit and sorbate through a traditional preparation process. Said invention also provides its application range.
Owner:杨毅男
Lactalbumin-oleic acid compound and carrageenan composite medicine as well as preparation method and application thereof
InactiveCN106267167AHigh conversion rateEasy to useAntibacterial agentsOrganic active ingredientsSuppositoryGlycerol
The invention discloses a lactalbumin-oleic acid compound and carrageenan composite medicine, which consists of 0.01-1 part by weight of a lactalbumin-oleic acid compound, 0.5-1.5 parts by weight of carrageenan, 1-3 parts by weight of carbomer, 1-5 parts by weight of glycerol and 0.1-0.2 part by weight of ethylparaben. The composite medicine is in the form of a gel, a suppository or a dressing. The composite medicine can be used for preventing and treating female human papilloma virus infection as well as for preventing and treating female gynecological gram negative bacterium infection.
Owner:深圳婕熹卡生物科技有限公司
Application of GW3965 in preparation of drugs treating or preventing hepatitis C
InactiveCN103054844ABroad-spectrum antiviral activityNovel targetPeptide/protein ingredientsDigestive systemAnti virusHepacivirus
The invention discloses application of GW3965 (3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2, 2)-biphenylethyl)amino]propoxy)phenylacetate hydrochloride) in preparation of drugs treating or preventing hepatitis C virus. A drug without any toxic concentration is chosen for an antiviral experiment, the influence of GW3965 on virus gene duplication is detected, and results show that the small molecule compound has significant antiviral activity and is dose dependent. Then, the GW3965 is employed to treat the hepatitis C pseudovirus system of different gene subtypes, and results show that the compound inhibits the virus entrance link at the early stage of a virus lifecycle. The anti-virus capability of drug combination of GW3965 and other anti-HCV drugs is detected, and results show that the compound has the potential of drug combination with other drugs. GW3965 can inhibit 1a, 1b, and 2a genotype virus entrance, and has broad-spectrum antiviral activity and a novel target, while there is no anti-hepatitis C virus drug with entrance as the target clinically. And drug combination can achieve a good effect.
Owner:WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
Application of cellular target liver X receptor in preparation of drugs treating hepatitis C virus
InactiveCN103063840AHigh cure rateHigh activityFluorescence/phosphorescenceLiver X receptorHepacivirus
The invention discloses application of a cellular target liver X receptor in preparation of drugs treating hepatitis C virus (HCV), specifically a cellular target that can be used for screening anti-HCV drugs. The cellular target is a liver X receptor (LXR). The agonist GW3965 and T0901317 of the liver X receptor have significant anti-hepatitis C activity in invitro anti-hepatitis C virus experiments. The cellular target liver X receptor can be used for screening drugs treating the hepatitis C virus. Therefore, the cellular target LXR involved in the invention can be applied to drug development as a new anti-hepatitis C virus target, thus providing a new approach and means for treatment and cure of hepatitis C.
Owner:WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
Chickweed polysaccharide composition and applications thereof in preparation of antiviral medicine
InactiveCN102697800ABroad-spectrum antiviral activityLow toxicityOrganic active ingredientsAntiviralsMannoseXylose
The invention relates to a chickweed polysaccharide composition and applications thereof in preparation of an antiviral medicine. The chickweed polysaccharide composition disclosed by the invention is prepared by mixing five kinds of chickweed polysaccharides (A, B, C, D and E) according to a certain proportion and is characterized in that the composition is of brown floccule which is easily dissolved in water and is not dissolved in ethanol, acetone, diethyl ether, n-butanol and isopropanol with high concentration; the polysaccharide composition contains five kinds of chickweed polysaccharides with molecular weights ranging from 5000 to 30000 and is formed by rhamnose, arabinose, xylose, mannose, glucose and galactose according to certain molar ratio. After being mixed uniformly in a special proportion, the five kinds of the polysaccharides can be used for strengthening antiviral activities by utilizing mutual synergy. The invention further discloses a use of the chickweed polysaccharide composition in preparation of the antiviral medicine, which is used for treating the diseases such as hepatitis B virus, HIV (human immunodeficiency virus), herpes virus, influenza virus, enterovirus and adenovirus and the like and can be prepared into various pharmaceutic preparations. The composition has a good therapeutic effect, no toxicity and wide prospect in development of new antiviral medicines.
Owner:贾晓斌
Application of doxylamine succinate in preparing drug for treating or preventing influenza virus
InactiveCN103251590AInhibition of replicationBroad-spectrum antiviral activityOrganic active ingredientsAntiviralsMedicineVirus strain
The invention discloses application of doxylamine succinate in preparing a drug for treating or preventing influenza virus. The application comprises the following steps of: selecting the doxylamine succinate with complete non-toxic concentration to carry out antiviral experiment, wherein the result shows that the micromolecule compound has remarkable antiviral activity and is dose-dependent; and detecting the antiviral activity of the doxylamine succinate to different types and subtypes of influenza viruses, wherein the result indicates that the doxylamine succinate has activity for detecting virus strain, a dose-dependent effect, as well as a certain broad-spectrum to the anti-influenza virus activity. Therefore, the doxylamine succinate disclosed by the invention can be developed as a novel anti-influenza virus drug, so that a novel way and means is provided for treating the influenza.
Owner:WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
Application of diethylstilbestrol to preparation of medicine for treating or preventing influenza virus infection
InactiveCN103877068ABroad-spectrum antiviral activityHydroxy compound active ingredientsAntiviralsCanine kidneyVirus influenza
The invention relates to the technical field of medicines and particularly discloses an application of diethylstilbestrol to preparation of a medicine for treating or preventing influenza virus infection. Firstly, the toxicity of diethylstilbestrol to an MDCK (madin darby canine kidney) cell is detected to obtain a result which shows that the maximum non-cytotoxic concentration of diethylstilbestrol is 25.0muM; secondly, the antiviral activity of diethylstilbestrol is detected within a complete non-cytotoxic concentration range to obtain a result which shows that the small-molecular compound has remarkable antiviral activity and the antiviral effect has a dose-dependent effect; finally, the antiviral activity of diethylstilbestrol to different types and subtypes of influenza viruses is detected to obtain a result which shows that diethylstilbestrol can inhibit the replication of all the detected influenza virus strains in a dose-dependent way, so that the anti-influenza virus activity of diethylstilbestrol is proved to have broad spectrum. Therefore, the invention firstly discloses diethylstilbestrol as a novel broad-spectrum anti-influenza virus medicine which can be used for preparing a medicine for preventing or treating influenza virus infection.
Owner:武汉胜达康生物科技有限公司
Application of carbinoxamine maleate in preparation of anti-influenza virus medicine
ActiveCN110870864BAvoid infectionBroad-spectrum antiviral activityOrganic active ingredientsAntiviralsPharmaceutical SubstancesInfluenza Viruses Type A
Owner:FUDAN UNIV
Application of nafronyloxalate in preparing medicine for treating or preventing influenza virus
InactiveCN103690522AImprove securityBroad-spectrum antiviral activityOrganic active ingredientsAntiviralsChemical compoundInfluenza treatment
The invention discloses application of nafronyloxalate in preparing a medicine for preventing or treating influenza virus. According to the application, first, the cytotoxicity of nafronyloxalate to MDCK (madin-darby canine kidney) cells is detected, and results indicate that CC50 (50% cytotoxic concentration) of the nafronyloxalate is 238.1mu M; secondly, nafronyloxalate with non-cytotoxic concentration is selected to be subjected to anti-virus experiments, and results indicate that the small molecular compound has a remarkable anti-virus activity and is related to dose dependence; finally, the anti-virus activity of the nafronyloxalate to different types and sub-type influenza viruses is detected, and results indicate that nafronyloxalate can be used for inhibiting replication of all detected virus strains and has a dose dependent effect, and the anti-virus activity of the nafronyloxalate has a certain broad-spectrum. Therefore, the nafronyloxalate can be used as a novel anti-virus medicine for developing, and a novel way and means is provided to influenza treatment.
Owner:武汉威立得生物医药有限公司
Application of enilconazole in preparing drug for treating or preventing influenza virus infections
InactiveCN103705506BImprove securityBroad-spectrum antiviral activityOrganic active ingredientsAntiviralsPharmaceutical SubstancesVirus strain
Owner:武汉威立得生物医药有限公司
Application of chlorpheniramine maleate in preparation of medicaments for treating or preventing influenza virus
InactiveCN103239446BInhibition of adsorptionInhibit entryOrganic active ingredientsAntiviralsVirus strainInfluenza a
The invention discloses application of chlorpheniramine maleate in preparation of medicaments for treating or preventing influenza virus. The application comprises the following steps of: first, performing an antivirus experiment by selecting the chlorpheniramine maleate with completely non-toxic concentration, wherein the result shows that the low molecular weight compound has remarkable antiviral activity and has dose-dependent correlation; then, analyzing the anti-influenza virus action cycle of chlorpheniramine maleate, wherein the result shows that chlorpheniramine maleate mainly inhibits the early virus infection events of virus adsorption, entry and the like; and finally, detecting the antiviral activity of chlorpheniramine maleate on different types or subtypes of influenza virus, wherein the result shows that chlorpheniramine maleate can inhibit the replication of all detection virus strains and has a dose-dependent effect, and shows that the anti-influenza virus activity of chlorpheniramine maleate has certain broad spectrum. Therefore, chlorpheniramine maleate disclosed by the invention can be developed as a new anti-influenza virus medicament, and provides a new way and a new means for treating the influenza virus.
Owner:WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
Anti-virus sterilizing purifying cleaning mixture
InactiveCN1624099AEasy to killEnhanced inhibitory effectNon-surface-active detergent compositionsAnti virusChemistry
An antiviral bactericiding liquid detergent is prepared from water, sodium benzoate, edible vinegar and its essence, garlic clove, onion and 8 Chinese-medicinal materials including cloves, cinammon bark, etc. Its advantages are broad bactericiding spectrum, high detergency, and high effect to prevent cold and infectious disease and improve human immunity.
Owner:杨毅男
Application of doxylamine succinate in preparing drug for treating or preventing influenza virus
InactiveCN103251590BInhibition of replicationBroad-spectrum antiviral activityOrganic active ingredientsAntiviralsVirus strainInfluenza a
The invention discloses application of doxylamine succinate in preparing a drug for treating or preventing influenza virus. The application comprises the following steps of: selecting the doxylamine succinate with complete non-toxic concentration to carry out antiviral experiment, wherein the result shows that the micromolecule compound has remarkable antiviral activity and is dose-dependent; and detecting the antiviral activity of the doxylamine succinate to different types and subtypes of influenza viruses, wherein the result indicates that the doxylamine succinate has activity for detecting virus strain, a dose-dependent effect, as well as a certain broad-spectrum to the anti-influenza virus activity. Therefore, the doxylamine succinate disclosed by the invention can be developed as a novel anti-influenza virus drug, so that a novel way and means is provided for treating the influenza.
Owner:WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
Spirocyclosporine x and its application in the preparation of medicaments for the treatment of influenza A
ActiveCN109336805BAvoid infectionBroad-spectrum antiviral activityOrganic active ingredientsOrganic chemistryArgininePhenylalanine
The invention discloses application of spirocyclosporin X to the preparation of a drug for treating influenza A. Influenza viruses are influenza A viruses and are preferably selected from H1N1, H3N2,H5N1 or H7N9. An action mechanism of the spirocyclosporin X in the anti-influenza A viruses is to inhibit the ribonucleoprotein complex vRNP activity by binding to PB2cap proteins; and the drug for preventing and treating the influenza is prepared. Sites at which the spirocyclosporin X binding to the influenza virus PB2cap proteins are arginine 355 (Arg355), asparagine 429 (Asn429), lysine 339 (Lys 339), methionine 431 (Met431) and phenylalanine 325 (Phe325).
Owner:广州南方医大科技园有限公司
Application of mepyramine maleate in preparing drug for treating or preventing influenza virus
InactiveCN103251591BInhibition of adsorptionInhibit entryOrganic active ingredientsAntiviralsMedicineInfluenza a
The invention discloses application of mepyramine maleate in preparing a drug for treating or preventing influenza virus. The application comprises the following steps of: selecting the mepyramine maleate with complete non-toxic concentration for carrying out an antiviral experiment, wherein the result shows that the compound has remarkable antiviral activity and is dose-dependent; analyzing an anti-influenza virus action period of the mepyramine maleate, wherein the result indicates that the mepyramine maleate can be mainly used for inhibiting virus infection early events including virus adsorption, virus entry and the like; and detecting the antiviral activity of the mepyramine maleate to different types and subtypes of influenza viruses, wherein the result shows that the mepyramine maleate can be developed as a novel anti-influenza virus drug, so that a novel way and means is provided for treating the influenza.
Owner:WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
Application of Protoporphyrin Derivatives in Preparation of Enveloped Virus Blocking Agent
ActiveCN111481558BBlock fusionImprove survival rateOrganic active ingredientsAntiviralsPorphyrinCell membrane
The invention discloses the application of protoporphyrin derivatives in the preparation of an enveloped virus blocking agent. The inventors found that protoporphyrin and its derivatives have broad-spectrum antiviral activity against influenza viruses including LASV, MERS, Ebola, SARS-CoV-2, and a series of different subtypes in vitro experiments, and the half inhibitory concentration is between Between 0.91~1.88μM. The possible mechanism is the biophysical interaction with the envelope lipids of enveloped viruses, thereby inhibiting the formation of a negative bending configuration of the envelope lipids and blocking the fusion between the virus envelope and the host cell membrane. At the same time, the in vivo model of mice infected with A / Puerto Rico / 8 / 34 (H1N1) virus strain was initially used to verify the antiviral effect of protoporphyrin. The results showed that the survival rate and survival time of mice in the administration group were significantly improved. improve. These research results suggest that the inventors can use protoporphyrin as a lead compound to establish an antiviral drug targeting the viral envelope to prevent and treat infectious diseases caused by enveloped virus infection.
Owner:广州肽山生物科技有限公司
Application of cepharanthine in preparation of anti-influenza virus drugs
ActiveCN114288297AHas anti-influenza virus activityAnti-influenza virus activity is obviousOrganic active ingredientsAntiviralsWhite blood cellCepharanthine
The invention discloses an application of cepharanthine in preparation of anti-influenza virus drugs in the technical field of medicines, and particularly relates to influenza A viruses, such as influenza viruses H1N1, H3N2, H5N1, H7N9, H9N2, H10N8 and the like. The invention aims to provide an application of a leukocyte hyperplasia drug cepharanthine in preparation of an anti-influenza virus infection drug, and discovers that cepharanthine has anti-influenza virus activity and can specifically destroy the activity of an influenza virus ribonucleoprotein complex vRNP so as to influence replication of influenza viruses for the first time. As a novel anti-influenza virus drug and a lead compound, cepharanthine has the characteristics of low toxicity, high activity, low price, easiness in obtaining and clear mechanism, can be used for developing novel anti-influenza virus drugs under existing application conditions, and has a relatively good application prospect.
Owner:SOUTHERN MEDICAL UNIVERSITY
Application of 1, 3-dyhydroxy-6-benzo[C]chromone to preparing anti-influenza virus drugs
ActiveCN107898783AAvoid infectionBroad-spectrum antiviral activityAntiviralsHeterocyclic compound active ingredientsChromonePhenylalanine
The invention discloses application of 1, 3-dyhydroxy-6-benzo[C]chromone to preparing anti-influenza virus drugs. Influenza viruses are influenza A viruses, preferably, H1N1, H3N2, H5N1, H7N1, H7N2, H7N3, H7N7, H7N9, H9N2 or H10N8; the mechanism of action of the 1, 3-dyhydroxy-6-benzo[C]chromone comprises binding with PB2cap protein to inhibit activity of vRNP (virus ribonucleoprotein complexes) to prepare drugs for preventing and treating influenza; the binding loci between the 1, 3-dyhydroxy-6-benzo[C]chromone and the PB2cap protein of the influenza viruses are His357 (histidine 357), Phe404(phenylalanine 404), Phe323, Glu361 (glutamic acid 361), Lys376 (lysine 376), Phe363 and Asn429 (asparagine 429).
![Application of 1, 3-dyhydroxy-6-benzo[C]chromone to preparing anti-influenza virus drugs](https://images-eureka.patsnap.com/patent_img/8decaaf5-c85d-4c35-937a-cb60427fba98/HDA0001470331700000011.png "Application of 1, 3-dyhydroxy-6-benzo[C]chromone to preparing anti-influenza virus drugs")
![Application of 1, 3-dyhydroxy-6-benzo[C]chromone to preparing anti-influenza virus drugs](https://images-eureka.patsnap.com/patent_img/8decaaf5-c85d-4c35-937a-cb60427fba98/HDA0001470331700000012.png "Application of 1, 3-dyhydroxy-6-benzo[C]chromone to preparing anti-influenza virus drugs")
![Application of 1, 3-dyhydroxy-6-benzo[C]chromone to preparing anti-influenza virus drugs](https://images-eureka.patsnap.com/patent_img/8decaaf5-c85d-4c35-937a-cb60427fba98/HDA0001470331700000021.png "Application of 1, 3-dyhydroxy-6-benzo[C]chromone to preparing anti-influenza virus drugs")
Owner:SOUTHERN MEDICAL UNIVERSITY
Features
- R&D
- Intellectual Property
- Life Sciences
- Materials
- Tech Scout
Why Patsnap Eureka
- Unparalleled Data Quality
- Higher Quality Content
- 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com